Cyclosporine A in Cardiac Arrest

Hospices Civils de Lyon796 enrolled

Overview

The investigators hypothesised that cyclosporine A administration at the onset of cardiopulmonary resuscitation, by inhibiting the mitochondrial permeability transition pore, could prevent the post cardiac arrest syndrome and improve outcomes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

796

Conditions

Non Shockable Out of Hospital Cardiac Arrest

Interventions

Cyclosporine ADRUG

Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation

cardio-pulmonary resuscitationPROCEDURE

usual care of cardiac arrest

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Witnessed out-of-hospital cardiac arrest * Non shockable cardiac rhythm Exclusion Criteria: * Evidence of trauma * Evidence of pregnancy * Duration of no flow more than 30 minutes * Rapidly fatal underlying disease * Allergy to cyclosporin A

Locations (1)

Medical intensive care unit, Edouard Herriot Hospital

Lyon, France

Outcomes

Primary Outcomes

Sequential Organ Failure Assessment score (SOFA)

Time frame: At 24 hours after hospital admission

Secondary Outcomes

Hospital admission with return of spontaneous circulation

Time frame: At 24 hours following admission, at day 28, at hospital discharge (an average time frame of 7 days)

Survival

Time frame: At 24 hours following admission, at day 28, and at hospital discharge (an average time frame of 7 days)

Good cerebral outcome

Glasgow Coma Scale and Cerebral Performance Categories

Time frame: At 24 hours following admission, at day 28, and at hospital discharge (an average time frame of 7 days)

All adverse events

Time frame: until hospital discharge (an average time frame of 7 days)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.